TREATMENT OF OBSTRUCTIVE PULMONARY DISEASE WITH BECLOMETOSONE/FORMOTEROL/GLYCOPYRRONIUM IN SINGLE INHALER. DATA FROM TRITRIAL REAL-LIFE TRIAL

Abstract

The TRITRIAL study assessed the effects of beclometasone dipropionate/formoterol fumarate/glycopyrronium (BDP/ FF/G) fixed combination in patients with chronic obstructive pulmonary disease (COPD) in a real-world setting through the use of patients reported outcomes. TRITRIAL was a multicenter, prospective, observational study conducted on patients with moderate-severe COPD treated with BDP/FF/G fixed therapy for 12 months. The main objective was to evaluate the impact of BDP/FF/G on health status through the COPD Assessment Test (CAT) score. Additional assessments included adherence and satisfaction, quality of life, sleep quality and disease-related outcomes. Data from 655 patients were analyzed in the study. The mean total CAT score significantly improved (from 22.8 at baseline to 18.1 at 6 months and 16.5 at 12 months; p < 0.0001), as well as all the eight CAT sub-items. Adherence, usability of the inhaler, quality of life and sleep quality significantly improved during the study. Finally, patients reported a significant reduction in exacerbation during the study. TRITRIAL showed that the BDP/FF/G fixed combination is effective in patients with moderate-severe COPD